Morning Overview on MSN
The FDA approved the first gene therapy for sickle cell in children as young as two
Regulators have opened a one-time gene therapy to some of the youngest patients with sickle cell disease. On July 1, 2026, ...
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug ...
By Yiqing Wang/WHRO State lawmakers have budgeted nearly $15 million over two years to help Virginia Medicaid cover gene ...
The Food and Drug Administration recently approved gene therapy to treat sickle cell disease among children ages 2 and older, which a Nashville doctor described as a medical milestone.
The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients ...
Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative approaches for blood diseases such as sickle cell disease, b-thalassemia, ...
Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.
From data lakes to streamlined production, Kriya, Opus, and Epicrispr discuss how technology is improving their operations.
SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced ...
Vijay Kumar, acting director of the office that reviews cell and gene therapies at the Food and Drug Administration, is ...
New Vericheck ddPCR™ Kits Combine Highly Specific and Highly Sensitive DNA Detection and Quantification with the QX700™ ...
Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results